# Nora Frey

> Nora Frey is a Series C investor at BioScience Managers Limited backing Medical and Biopharma. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BioScience Managers Limited](https://shizune.co/investors/profile/bioscience-managers-limited)
- Total investments: 2
- Last investment: Oct 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/nora-frey-4299b349

Nora Frey is a Series C investor at BioScience Managers Limited focused on Medical and Biopharma. Nora studied modern biology (microbiology, biochemistry) and economics in Basel and holds a masters degree in Microbiology and a PhD in Biochemistry in the field of drug-induced autoimmune diseases from the University of Basel.She was partner at Bellevue Group, Zug, Switzerland and part of the BB Biotech management team managing up to CHF 4B inpublic and private biotech investments. In 2000 she conceived and founded Adamant Biomedical Investments AG in Basel, Switzerland.Among several other awards, Nora was voted finalist in the Ernst &Young Entrepreneur of the Year Award in Switzerland. She was responsible for the establishment of a subsidiary of Adamant, Adamant Ventures Ltd., in Edinburgh, UK.Towards the end of 2008, Nora left Adamant to found Cederberg Advisors.Nora is a citizen of Germany and Switzerland.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Biopharma | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 1 | 50% |
| Series D | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vertero | Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $37.3M | Series C | Oct 13, 2021 |  |
| Vertero | Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $20M | Series D |  |  |

2 of 2 investments shown.

## Co-investors
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Longwood Fund](https://shizune.co/investors/profile/longwood-founders-fund) — VC Fund, 2 deals together
- [OneVentures](https://shizune.co/investors/profile/one-ventures) — VC Fund, 2 deals together
- [Autism Impact Fund](https://shizune.co/investors/profile/autism-impact-fund) — VC Fund, 1 deal together
- [Corundum Systems Biology](https://shizune.co/investors/profile/corundum-systems-biology) — VC Fund, 1 deal together
- [Taiho Ventures](https://shizune.co/investors/profile/taiho-ventures-2) — VC Fund, 1 deal together

## About BioScience Managers Limited

VC Fund · Melbourne, Australia

BioScience Managers Pty Ltd (formerly IB Managers) is a leading life sciences investment firm, headquartered in Melbourne, Australia. Established in 2003, BioScience Managers offers a global, multi-disciplinary team, bringing an international perspective together with the track record, networks and expertise required to convert that perspectiveinto informed, high return investment decisions.We operate a high value-add model, providing assistance and support to portfolio companies via our global team and international network of independent industry advisors. With combined experience of over 170 investments, more than 40 IPO’s/ reversals in Europe, the USA and Australia, and a diverse skillset specific to the bio-based industries, we aim to provide investee companies with significant value-add over and above capital invested.Alongside our funds management business, Phillip Bioscience Advisory provides specialist corporate advisory services to healthcare and life sciences companies.

5 contacts available at BioScience Managers Limited.

| Name | Title | Profile |
| --- | --- | --- |
| Amanda Gillon | Investment Analyst | https://shizune.co/investors/profile/amanda-gillon |
| Matt McNamara | Managing Director | https://shizune.co/investors/profile/matt-mcnamara |
| Nora Frey | Investment Manager | https://shizune.co/investors/profile/nora-frey |
| Bronwyn Dilley | senior executive | https://shizune.co/investors/profile/bronwyn-dilley |
| Jeremy Curnock Cook | Manager | https://shizune.co/investors/profile/jeremy-curnock-cook |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Nora Frey invest in?

Nora Frey invests primarily in Medical, Biopharma and Biotechnology startups, most often at Series C and Series D stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Nora Frey last invest?

The most recent investment recorded for Nora Frey closed in Oct 2021. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co